Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 8902 results

  1. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  2. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Withdrawn guidance

  3. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  4. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  5. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  6. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  7. Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

    We have withdrawn this guidance. Grünenthal has stopped marketing Lesinurad (Zurampic) for commercial reasons and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  8. Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)

    This guidance has been updated and replaced by NICE technology appraisal guidance 97.

    Withdrawn guidance

  9. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

    This guidance has been updated and replaced by NICE technology appraisal guidance 783.

    Withdrawn guidance

  10. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Withdrawn guidance

  11. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 151.

    Withdrawn guidance

  12. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)

    This guidance has been updated and replaced by NICE technology appraisal guidance 897.

    Withdrawn guidance

  13. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Withdrawn guidance

  14. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  15. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Withdrawn guidance